Suneva Medical Has Acquired Rights to Refissa®

May 21, 2012 – Suneva Medical, a privately-held aesthetics company, has acquired the worldwide rights to Refissa® and its marketed generic equivalent. The portfolio contains the only tretinoin creams with a 0.05% strength, emollient base and broad indication for fine facial lines, hyper pigmentation, and tactile roughness. Refissa® is formulated in a moisturizing base and is an ideal option for mature patients with drier, more sensitive photo damaged skin.

Important Safety Information: Refissa 0.05% is a prescription medicine that may reduce fine facial wrinkles and mottled hyperpigmentation in patients who also protect their skin from the sun and wear sunscreen daily. Refissa does not eliminate wrinkles, repair sun damaged skin or reverse photo-aging. Avoid medicines that may increase your sensitivity to sunlight, ask your pharmacist. Do not use if you are pregnant, attempting pregnancy, or nursing. Refissa, early in treatment, may cause redness, itching, burning, stinging and peeling. Please see Full Prescribing Information at www.refissa.com.